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Abstract
There is increasing concern among many in the medical arena about the extent to which the effects
of treatment, either good or bad, apply to specific subgroups of individuals. Women comprise one
of the most frequently considered 'subgroups' of patients. In the 1980s, much political attention
was focused on concerns about equity in the research enterprise. In this paper, we briefly describe
the statutory approaches to achieving equity in research, beginning with The NIH Revitalization Act
of 1993. We go on to describe clinical, methodological and political factors affecting these
discussions. We conclude that the controversy over the inclusion of women in clinical trials
probably stems, in part, from theoretical concerns about gender differences in treatment effects
and, in part, by legitimate fears of exposing fetuses to investigational drugs. However, we believe
that the broader issue centres on biological factors, possibly defined by genes or gene expression,
that may directly or indirectly modify the effect of specific treatments on specific individuals.
A growing concern of physicians, regulators, healthcare policy makers and patients is the extent to
which the effects of treatment, both good and bad, apply to specific subgroups. Do results of clinical
trials apply consistently and equally across all clinically meaningful subclasses of patients enrolled in
the studies? Can the results of those studies be extrapolated to patients or types of patients who
did not participate in the original research? Reliable data on these issues are rarely available at the
time of drug approval and are more difficult to generate once the drug is on the market and readily
available.
Inclusion of women in trials
Women comprise one of the most frequently considered
'subgroups' of patients for many medical conditions.
Beginning in the 1980s, a great deal of political attention
was focused on the concerns about equity in the research
enterprise. Trials, such as the Multiple Risk Factor Inter-
vention Trial [1,2] and the Physicians' Health Study [3,4],
both primary prevention trials, studied only men. This
was because of the lower incidence of cardiovascular dis-
ease among middle-aged women, the desire to minimize
heterogeneity of the trial population and, in the case of
the Physician's Health Study, the small proportion of
female physicians available at the time that the study was
undertaken. These practical considerations relied on the
underlying assumption that the treatment effects in
women would be similar to those in men, an assumption
that became increasingly challenged [5-7].
Meinert and colleagues [8] argued that there was little evi-
dence to support the perception that women were under-
represented in trials. Even in trials for heart disease, nearly
68% involved both men and women These authors sug-
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gested that in heart disease, as well as in HIV, the direc-
tions of the male-female differences are consistent with
the burden of disease. They further noted that for neo-
plasms, female-only trials (20.8%) outnumbered male-
only trials (8.7%) by a substantial margin.
Nevertheless, concerns about the exclusion of women
from some trials of important medical issues led to the
NIH Revitalization Act of 1993 [9] The Act mandated that
NIH-funded trials have sample sizes adequate to support
a 'valid analysis' of gender and racial subgroup effects. The
statute allows exceptions to the requirement for entering
women and minorities when there is substantial evidence
of the lack of difference in effects of treatment between
subgroups.
While the 1993 legislation was primarily motivated by
concerns about understanding the effects of treatment on
women, controversies were brewing for other reasons.
Women with child-bearing potential had long been
excluded from clinical trials due to concerns about expos-
ing fetuses to experimental drugs. This convention was
challenged in the 1990s when HIV-infected women found
themselves ineligible to participate in trials of new antivi-
ral therapies; at a time when very few such therapies were
available, the potential benefits of having access to a new
treatment for this life-threatening disease appeared to
most women to outweigh any possible risks [7]. In
response to these concerns, the FDA took formal steps to
facilitate the inclusion of premenopausal women into
clinical trials under certain circumstances [10].
A related, and even more challenging problem, was the
treatment of pregnant women. There is a widespread
reluctance to expose pregnant women to investigational
drugs because of possible risks to developing fetuses. The
implication of this situation, however, is that pregnant
women who get sick, who have chronic diseases requiring
maintenance medication or who face a risk (for example,
who possibly need a new vaccine) are unable to weigh the
potential benefits against the potential risks, since there
will be no data on treatment effects in pregnant women.
Pregnant women who must take certain medications are
essentially participating in an uncontrolled and unmoni-
tored experiment for which the data will most likely never
be assessed. A possible exception may be trials of the
H1N1 flu vaccine; pregnant women are considered part of
the high-risk group for this infection and there have been
indications that pregnant women will be included in later
cohorts of the clinical trials [11].
Methodological Issues in Assessing Treatment 
Effects in Subgroups
The exploration of treatment effects in patient subgroups
has been controversial. Most trials are not designed with
sample sizes that are large enough to detect moderate
interactions in treatment effects among subgroups or to
develop precise estimates of the effects within subgroups.
Meta-analysis of completed clinical trials may be useful
for exploring these questions with improved statistical
power, but often there are no multiple studies that are suf-
ficiently similar to support an informative meta-analysis.
Freedman and colleagues [12], in their commentary on
the 1993 legislation described above, stress the impor-
tance of using appropriate methods to compare interven-
tion effects among gender and racial/ethnic subgroups.
They stress the possibilities of finding clinically unimpor-
tant but statistically significant differences, and vice versa.
In fact, they go on to argue against designing trials with
sufficient power to detect treatment by subgroup interac-
tions in the absence of a priori evidence that such sub-
group differences might exist. (How one generates this a
priori evidence is left unclear.) Clinical trialists recognize
that the requirement that all studies should be powered
statistically to detect treatment X gender (or other) inter-
actions would make trials infeasible. Freedman et al. also
suggest that meta-analysis of multiple trials is the best way
to obtain reliable information about subgroup differ-
ences.
Differences in treatment effect across subgroups of
patients do not all have the same implications. The type
of difference that might cause the most concern would be
a directional difference: one group benefits from the treat-
ment while the other is harmed. Such differences are rare;
when they have been occasionally suggested they have
generally not been supported by other data [13-15]. It
would also be important to be aware of a difference in
magnitude of effect if the difference was substantial, as it
would affect risk-benefit considerations. There are a few
examples of this phenomenon. One recent example, of a
heart failure drug that appeared effective in African Amer-
icans but ineffective in whites, remains controversial but
is supported by data from multiple studies [16,17].
The NIH Office of Research in Women's Health maintains
data on the inclusion of women in NIH-funded trials. The
most recent report shows that women comprise approxi-
mately 55% of clinical trial participants [18]. Overall
numbers, however, may be less informative than they
seem. For example, although the annual incidence of
breast cancer is about the same as that for prostate cancer,
enrollment in breast cancer trials is much higher than in
prostate cancer trials [19]. Many other diseases are not
gender neutral; more women get autoimmune diseases;
more boys are diagnosed with ADHD. When there are
exciting new molecules to study in a given medical area,
trials in this area may have a greater advantage, thereby
contributing to an artifactual gender imbalance in trialPublish with BioMed Central    and   every 
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participants. These confounding issues, which may have
their own time trends, make it difficult to assess the extent
to which men and women are proportionally represented
in trials of disease affecting both genders.
In summary, controversy over the inclusion of women in
clinical trials has been motivated, in part, by theoretical
concerns about gender differences in the effect of the treat-
ment and, in part, by legitimate fears of exposing fetuses
to investigational drugs. There is no question that some
treatments do work differently in men and women, but
the proportion of treatments for which men and women
respond very differently is unknown. The broader issue
really centres on biological factors, possibly defined by
genes or gene expression, that may directly or indirectly
modify the effect of specific treatments on specific indi-
viduals. Whether the current explosive interest in genetic
profiling will ultimately lead to the medical nirvana of
personalized medicine, that many have predicted,
remains to be seen.
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